• Target indication: bacterial vaginosis and other anaerobic infections.

    Bacterial vaginosis (BV) is common gynecological disease with the incidence rate of 15-64%. BV can cause ectopic pregnancy in women of childbearing age and greatly increase the risk of transmission of infectious diseases. BV is associated with a number of anaerobic bacteria that have developed resistance to current antibiotics and are able to form bacterial biofilms that are persistent to antibiotic therapy. Currently the first-line therapy for the treatment of BV is oral or suppository metronidazole with an annual recurrence rate as high as 80%.

    TNP-2198 is a multi-targeting New Molecular Entity with a synergistic mode of action against anaerobic bacteria. The compound is highly potent against pathogens associated with BV, including those that are resistant to metronidazole and other antibiotics. The compound has demonstrated a low propensity for resistance development and activities against pathogens living in bacterial biofilms. The compound has demonstrated excellent efficacy in multiple animal infection models.